期刊文献+

无菌体液白色假丝酵母菌感染分布及耐药特点

Distribution and drug resistance of Candida albicans infection in sterile body fluid.
原文传递
导出
摘要 目的 分析我院近5 年住院患者无菌体液标本白色假丝酵母菌分布及其耐药情况,为临床诊治提供依据.方法 收集我院2011年01 月至2015 年12 月住院患者送检无菌体液标本,对分离出的真菌进行培养和鉴定,分析白色假丝酵母菌的分布及其耐药情况.结果 我院无菌体液标本共分离出白色假丝酵母菌为98 株,其标本来源主要来自血液,其次为腹水、胸水;与2011 年比较,2013、2014、2015 年每年感染白色假丝酵母菌有明显增加趋势,P 值均小于0.05,但对各类抗真菌药物的耐药率较低.结论 临床无菌体液标本中检出白色假丝酵母菌主要标本为血液,其次为腹水、胸水,每年感染白色假丝酵母菌有明显增加趋势,体外药敏总体耐药率均低. Objective To analyze the distribution and drug resistance of Candida albicans in the sterile body fluid of hospitalized patients in ourhospital in the past 5 years, and to provide the evidence for clinical diagnosis and treatment. Methods Hospitalized patients with sterile fluids wereisolated,cultured and identified from January 2011to December 2015 in our hospital,analyzed distribution and drug resistance of Candida albicans. Results98 strains of Candida albicanswere isolated from the sterile body fluid specimens in our hospital, the mainly source of the specimens was blood, followedby the ascites, pleural effusion; And the years of 2011, 2013, 2014, 2015 annual infection Candida increased significantly, P values were less than 0.05, butthe resistance rate was low on all kinds of antifungal drug . Conclusions The main samples of the Candida albicans were detected in the clinical samplesof sterile fluid was blood, followed by ascites and pleural effusion, and the rate of the Candida albicans infection increased significantly years byyears.But the rate of drug resistance was very low.
作者 谭乃英
出处 《中华临床医师杂志(电子版)》 CAS 2016年第7期22-23,共2页 Chinese Journal of Clinicians(Electronic Edition)
关键词 无菌体液 白色假丝酵母菌 耐药性 sterile fluids Candida albicans drug resistance
  • 相关文献

参考文献4

二级参考文献27

  • 1姚正国,黄宪章,范秋莲,肖华,姚月球.酵母菌对氟康唑的药物敏感试验分析[J].中华医院感染学杂志,2004,14(4):443-444. 被引量:4
  • 2杨蓬勃,胡云建.住院患者真菌感染及耐药性分析[J].中华医院感染学杂志,2007,17(6):729-731. 被引量:41
  • 3Lrpez Moral L, Tiraboschi IN, Schijman M, et al. Fungemia in hospitals of the City of Buenos Aires, Argentina [ J ]. Rev Iberoam Micol,2012, 29:144-149.
  • 4Munoz P, Burillo A, Bouza E, Criteria used when initiating antifungal therapy against Candiada spp. in the intensive care unit[ J ]. Int J An- timicrob Agent,2000,15 (2) :83-90.
  • 5Maiken Cavling Arendrup, Brita Bruun. National surveillance of funge- mia in Denmark (2004 to 2009) [ J]. J Clin Mierobiol,2011,49( 1 ) : 325 -334,.
  • 6Gonza'lez GM, Mariana E ,Jacobo A. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monter- rey, Mexico, to seven antifungal agents : Results of a 3-year ( 2004 to 2007) surveillance study [ J ]. J Clin Microbiol, 2008,46 ( 9 ) : 2902- 2905.
  • 7Wisplinghoff H, Ebbers J, Geurtz L, et al. Nnsocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities [ J ]. Int J Antimicrob Agents, 2014, 43(1): 78-81.
  • 8Spampinato C, Leonardi D. Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents [J]. Biomed Res Int, 2013, 2013: 204237.
  • 9Munoz P, Burillo A, Bouza E. Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit[J]. Int J Antimicrob Agent,2000,15(2):83-90.
  • 10Lrpez Moral L,Tiraboschi IN, Schijman M, et al. Fungemia in hospitals of the City of Buenos Aires Argentina[J]. Rev Iberoam Micol,2012,29(4): 144-149.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部